We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients.
- Authors
Nalluri, Shobha Rani; Chu, David; Keresztes, Roger; Xiaolei Zhu; Shenhong Wu
- Abstract
The article presents a meta-analysis which assesses the risk of venous thromboembolism associated with bevacizumab. Bevacizumab is described as a treatment for many types of malignancies. Relevant trials for the analysis were identified through searches of PubMed and Web of Science databases for articles and abstracts presented at American Society of Clinical Oncology conferences. Randomized controlled trials which involved standard antineoplastic therapy with and without benvacizumab and which included data on venous thromboembolism were selected for the study. A discussion of the statistical analysis is included. Results of the analysis indicated that the risk for all-grade and high-grade venous thromboembolism was significantly increased for patients treated with bevacizumab.
- Subjects
META-analysis; THROMBOEMBOLISM risk factors; BEVACIZUMAB; RANDOMIZED controlled trials; CANCER patients; CANCER treatment
- Publication
JAMA: Journal of the American Medical Association, 2008, Vol 300, Issue 19, p2277
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2008.656